First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ER Plimack, NM Hahn, Ronald de Wit, L Pang, MJ Savage, RF Perini, SM Keefe, D Bajorin, J Bellmunt

Research output: Contribution to journalArticleAcademicpeer-review

887 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1483-1492
Number of pages10
JournalLancet Oncology
Issue number11
Publication statusPublished - 2017

Cite this